PharmAbcine Announces Korean Patent Grant for TIE2-Activating Antibody 바카라 카지노403

[by Kang, In Hyo] PharmAbcine Inc., a clinical-stage biotech company specializing in next-generation antibody therapeutics, announced on November 7th that its novel TIE2-activating antibody PMC-403 has been granted a Korean patent, following approvals in Japan, China, Canada, Singapore, and Russia.

The company expects additional 바카라 카지노s to be granted in the United States, Europe, Australia, Brazil, Mexico, and India in due course.

The newly issued patent covers the manufacturing method, pharmaceutical composition containing the antibody as an active ingredient, and combination compositions comprising other agents that bind to TIE2. This reinforces PharmAbcine’s intellectual property portfolio around vascular stabilization via TIE2 activation.

바카라 카지노403 is a first-in-class human IgG antibody that specifically binds to TIE2 receptors to restore endothelial tight junctions, reduce vascular leakage, normalize vessel function through receptor phosphorylation, and suppress inflammation.

The drug is currently being evaluated in a Phase I clinical study in 바카라 카지노 patients with neovascular (wet) age-related macular degeneration (AMD) who are resistant to standard anti-VEGF therapies, which account for approximately 50% of AMD patients. All dosing has been completed, and the Clinical Study Report (CSR) is expected to be finalized by the end of 2025.

This clinical study was supported by research funding from the 바카라 카지노 Drug Development Fund (KDDF).

Beyond ophthalmology, 바카라 카지노403 has shown broad vascular-stabilizing activity in systemic disease models, including cancer, chronic kidney disease (CKD), systemic capillary leak syndrome (SCLS), pulmonary disorders, and autoimmune diseases, when administered via intravenous routes. PharmAbcine plans to further explore these therapeutic indications.

Dr. Jin-San Yoo, Executive Vice President of PharmAbcine, has been invited to present the latest clinical and preclinical results of PMC-403 at two upcoming conferences: the Korean Society for Vascular Biology Annual Meeting (Daejeon, Korea, November 7–8, 2025) and The 4th Antibody Society of Japan Annual Symposium (Saitama, Japan, December 1–3, 2025).

PharmAbcine is also developing multi-target antibody programs based on the 바카라 카지노403 platform, including a government-funded project exceeding KRW 6 billion aimed at treating rare pediatric retinal vascular diseases that cause blindness.

According to Dr. Yoo, “The PMC-403 platform enables us to develop various next-generation biologics that may address a broad spectrum of vascular dysfunction-related diseases — not only in ophthalmology but also in aging, cancer, diabetes, infection, genetic, neurological, and traumatic conditions. We are actively pursuing global collaborative research partnerships to advance this platform.”

Meanwhile, the company noted that it has filed an injunction with the court against the KOSDAQ delisting decision and is currently awaiting the court’s ruling.